E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045365 |
E.1.2 | Term | Ulcerative colitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether LY3471851 is superior to placebo in inducing clinical remission in participants with moderately to severely active Ulcerative Colitis (UC)
|
|
E.2.2 | Secondary objectives of the trial |
•To evaluate the efficacy of induction treatment with LY3471851 compared to placebo with respect to clinical, endoscopic, and histologic improvement •To evaluate the efficacy of maintenance treatment with LY3471851 compared to placebo with respect to clinical, endoscopic, and histologic improvement •To evaluate the efficacy of treatment with LY3471851 compared to placebo with respect to patient-reported outcomes and quality of life measures •To evaluate the PK of LY3471851 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Are male or female patients ≥18 and ≤80 years of age at the time of initial screening •Have moderately to severely active ulcerative colitis (UC) as defined by a modified Mayo score (MMS) of 4 to 9 with an endoscopic subscore (ES) ≥2, with endoscopy performed within 14 days before baseline •Have an established diagnosis of UC of ≥3 months in duration before baseline (Week 0) •Have evidence of UC extending proximal to the rectum (with ≥15 centimeter (cm) of involved colon) •Have up-to-date colorectal cancer surveillance performed according to local standard •Participants are either one of the following: -Have failed conventional treatments including inability to tolerate oral or intravenous corticosteroids or immunomodulators (6-mercaptopurine or azathioprine or methotrexate), or history of corticosteroid dependence and neither failed or demonstrated intolerance to advanced OR, -Have failed or demonstrated intolerance to advanced therapies such as treatment with 1 or more advance therapies (eg, tumor necrosis factor [TNF} antagonists, anti-integrin therapies, anti- IL12/23p40 therapies, Janus kinase [JAK] inhibitor) |
|
E.4 | Principal exclusion criteria |
•Have been diagnosed with indeterminant colitis, proctitis (colitis limited to the rectum only; less than 15 centimeter (cm) from the anal verge or Crohn’s disease • Have had or will need abdominal surgery for UC (for example, subtotal colectomy) •Have failed 3 or more classes of advanced therapies approved for treatment of UC (eg, tumor necrosis factor [TNF] antagonists, anti-integrin therapies, anti-IL12/23p40 therapies, Janus kinase [JAK] inhibitor) •Have evidence of active tuberculosis (TB), or have a past history of active TB, regardless of treatment, or are diagnosed with latent tuberculosis infection (LTBI) at screening •Have human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), or acute or chronic hepatitis B infection or current hepatitis C infection •Have had recent clostridium difficile , cytomegalovirus or other intestinal infection •Have had lymphoma, leukemia, or any malignancy within the past 10 years •Are pregnant, breastfeeding, or planning pregnancy (women only), or within 20 weeks after receiving the last dose of study agent |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Difference in the proportion of participants who achieve clinical remission at Week 12
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
•Difference between LY3471851 and placebo in the proportion of participants who have not permanently discontinued at Week 12 and have achieved at Week 12: clinical response, endoscopic remission, endoscopic response, symptomatic remission, symptomatic response, histologic remission, histologic-endoscopic mucosal healing •Difference between LY3471851 and placebo in the proportion of participants who were responders at Week 12 (Week 12 Responders) and have not permanently discontinued at Week 52, who at Week 52 still have: clinical remission, clinical response, endoscopic remission, endoscopic response, symptomatic remission, symptomatic response, histologic remission, histologic-endoscopic mucosal healing •Comparison of mean changes from baseline to Week 12 and to Week 52 in scores for: IBDQ, Urgency NRS, Abdominal Pain NRS, Nocturnal Stools, Bristol Stool Scale, PGR-S, Fatigue NRS •Week 12 LY3471851 trough concentrations |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Week 12, Week 12 to 52 and Week 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 63 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Brazil |
Canada |
China |
Georgia |
India |
Israel |
Japan |
Korea, Republic of |
Russian Federation |
Ukraine |
United States |
Belgium |
France |
Germany |
Hungary |
Latvia |
Poland |
Romania |
Slovakia |
United Kingdom |
Czechia |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last visit for the last participant in the study globally |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |